

EMA/847176/2022

Agenda – Workshop on myocarditis post COVID-19 vaccination 16 January 2023 13.00 – 18:30 CET

Time	Торіс	Speakers			
13:00 - 13:05	Welcome and adoption of agenda	Marco Cavaleri (EMA) & Sabine Straus (PRAC)			
Session 1. Population-based studies and Clinical features of vaccine and infection induced myocarditis Chair: Georgy Genov and Menno van der Elst					
13:05 - 13:20	Global overview of vaccine related myocarditis	Kristine Macartney, GACVS member and Director, NCIRS			
13:20 - 13:35	Impact of Booster Dose and Dosing Interval	Stéphane Le Vu, ANSM			
13:35 - 13:50	Incidence, follow-up, and pathophysiology of myocarditis following mRNA vaccine in Israel: Results of an Active Surveillance	Dror Mevorach, Division of Rheumatology- Immunology-Allergology Hadassah Medical Center			
13:50 - 14:05	Myocarditis after mRNA COVID-19 vaccines: Vaccine Safety Surveillance in the United States	John Su, US CDC			
14:05 - 14:20	Myocarditis Presentation and Outcomes following Vaccination and Viral Infections	Leslie Cooper, Mayo Clinic (cancelled)			
14:20 - 14:35	COVID-19 Vaccine BNT162b2 Myocarditis	Claudia Ana Ianos and Heather Rubino, Pfizer- BioNTech			
14:35 - 14:50	Moderna COVID-19 vaccines and the risk of myocarditis: review of current data and planned studies	Walter Straus, Moderna			
14:50 - 15:05	Myocarditis postmarketing safety	Christopher Mast, Novavax			
15:05 - 15:30	Discussion	all			

Break 15'

Session 2. Disease mechanism and molecular findings Chair: Marco Cavaleri and Jean-Michel Dogné

 Official address
 Domenico Scarlattilaan 6
 1083 HS Amsterdam
 The Netherlands

 Address for visits and deliveries
 Refer to www.ema.europa.eu/how-to-find-us

 Send us a question
 Go to www.ema.europa.eu/contact
 Telephone +31 (0)88 781 6000



An agency of the European Union

© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged.

Session 2. Disease mechanism and molecular findings Chair: Marco Cavaleri and Jean-Michel Dogné

15:45 - 16:00	Integrated analysis of transcriptomic and epigenomic signatures of peripheral immune cells in the patient of BNT162b2-induced myocarditis	Bo Kyung Yoon, Yonsei University
16:00 - 16:15	Circulating Spike Protein Detected in Post-COVID- 19 mRNA Vaccine Myocarditis	Lael Yonker, Massachusetts General Hospital for Children
16:15 - 16:30	Implications of sex differences in myocarditis on post-COVID vaccination myocarditis	Katelyn Bruno, University of Florida
16:30 - 16:45	Innate immune mechanisms of mRNA vaccines	Rein Verbeke, University of Ghent
16:45 - 17:00	IL-1RA Antibodies in Myocarditis after SARS-CoV-2 Vaccination	Lorenz Thurner and Christoph Kessel, Saarland University
17:00 - 17:15	Lack of evidence of significant homology of SARS- CoV-2 spike sequences to myocarditis-associated antigens	Alessandro Sette, La Jolla Institute of Immunology
17:15 - 17:25	Mechanisms of myocarditis post COVID-19 vaccination	Alida Caforio, University of Padova
17:25 - 17:32	Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination	Peter Schirmacher, University Hospital Heidelberg
17:33 - 17:40	Decoding of the human genetic and immunological basis of COVID-19 mRNA vaccine-induced myocarditis	Alexandre Bolze, Helix
17:40 - 18:10	Discussion	all

Session 3. Concluding remarks Chair: Marco Cavaleri				
18:10 - 18:25	Conclusions and wrap-up	Marco Cavaleri (EMA) &		
		Sabine Straus (PRAC), all		